Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774267 · ClinicalTrials.gov registry record
Study Evaluating Changes In Mammographic Breast Density
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 507
- Enrollment target
NCT00774267: Completed study, sponsored by Pfizer.
NCT00774267 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 507 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00774267 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 507 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.
Primary Outcome
The digitized mammogram pairs were analyzed by a single trained radiologist who determined the density of the breast using software. The only left craniocaudal view was used for assessing breast density.
Interventions
- DRUG Placebo
- DRUG BZA 20 mg/CE 0.45 mg
- DRUG BZA 20 mg/CE 0.625 mg
- DRUG Raloxifene 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-04 |
What the finished NCT00774267 record still lists
NCT00774267 is an observational study that tracks outcomes without assigning an intervention. The registered 507 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00774267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00774267 about?
NCT00774267 is a clinical study titled "Study Evaluating Changes In Mammographic Breast Density". The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mam...
What is the current status of trial NCT00774267?
This trial is currently completed. The enrollment target is 507 participants. The study started on 2009-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00774267?
The interventions under investigation include: Placebo (DRUG), BZA 20 mg/CE 0.45 mg (DRUG), BZA 20 mg/CE 0.625 mg (DRUG), Raloxifene 60 mg (DRUG).
Who is sponsoring clinical trial NCT00774267?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia